Idenix Pharmaceuticals (IDIX) Tops Q3 EPS by 6c; Retains Worldwide Rights to Develop and Commercialize IDX184
Tweet Send to a Friend
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) reports a Q3 loss of $0.18, 6 cents better than the analyst estimate of ($0.24) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
